Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review.

IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Current Hypertension Reviews Pub Date : 2021-01-01 DOI:10.2174/1573402116666200804153228
Ricardo Cohen, Noelia S Sforza, Romina G Clemente
{"title":"Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review.","authors":"Ricardo Cohen,&nbsp;Noelia S Sforza,&nbsp;Romina G Clemente","doi":"10.2174/1573402116666200804153228","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The association between obesity and a reduction in life expectancy is well established, and cardiovascular disease is a leading cause of mortality. Bariatric surgery has long been established as the most effective and durable intervention for obesity, and is the only intervention for obesity that consistently improves multiple comorbidities, reduces cardiovascular disease and long-term mortality. The purpose of this review is to describe the impact of metabolic/bariatric surgery on type 2 diabetes mellitus and cardiometabolic parameters, including cardiovascular mortality.</p><p><strong>Methods: </strong>A systematic literature search of Pubmed, MEDLINE, and Cochrane Central Register was performed. We included randomized controlled trials, meta-analysis, case-control trials, and cohort studies that contain data on reductions in cardiovascular risk factors and cardiovascular mortality in subjects who underwent metabolic/bariatric surgery from January 1, 2005 to June 1, 2020.</p><p><strong>Conclusion: </strong>There is sufficient evidence from randomized controlled trials that metabolic/bariatric surgery is associated with a significant improvement of all cardiovascular risk factors. Although studies are showing a reduction of macrovascular events and cardiovascular mortality, these findings come from observational studies and should be confirmed in randomized clinical trials.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573402116666200804153228","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 2

Abstract

Background: The association between obesity and a reduction in life expectancy is well established, and cardiovascular disease is a leading cause of mortality. Bariatric surgery has long been established as the most effective and durable intervention for obesity, and is the only intervention for obesity that consistently improves multiple comorbidities, reduces cardiovascular disease and long-term mortality. The purpose of this review is to describe the impact of metabolic/bariatric surgery on type 2 diabetes mellitus and cardiometabolic parameters, including cardiovascular mortality.

Methods: A systematic literature search of Pubmed, MEDLINE, and Cochrane Central Register was performed. We included randomized controlled trials, meta-analysis, case-control trials, and cohort studies that contain data on reductions in cardiovascular risk factors and cardiovascular mortality in subjects who underwent metabolic/bariatric surgery from January 1, 2005 to June 1, 2020.

Conclusion: There is sufficient evidence from randomized controlled trials that metabolic/bariatric surgery is associated with a significant improvement of all cardiovascular risk factors. Although studies are showing a reduction of macrovascular events and cardiovascular mortality, these findings come from observational studies and should be confirmed in randomized clinical trials.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
代谢手术对2型糖尿病、心血管危险因素和死亡率的影响:综述
背景:肥胖与预期寿命缩短之间的关系已得到证实,而心血管疾病是导致死亡的主要原因。减肥手术长期以来一直被认为是最有效和持久的肥胖干预措施,也是唯一一种持续改善多种合并症、减少心血管疾病和长期死亡率的肥胖干预措施。本综述的目的是描述代谢/减肥手术对2型糖尿病和心脏代谢参数的影响,包括心血管死亡率。方法:系统检索Pubmed、MEDLINE和Cochrane Central Register的文献。我们纳入了随机对照试验、荟萃分析、病例对照试验和队列研究,这些研究包含了2005年1月1日至2020年6月1日期间接受代谢/减肥手术的受试者心血管危险因素和心血管死亡率降低的数据。结论:有足够的随机对照试验证据表明,代谢/减肥手术与所有心血管危险因素的显著改善有关。虽然研究显示大血管事件和心血管死亡率降低,但这些发现来自观察性研究,应在随机临床试验中得到证实。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Hypertension Reviews
Current Hypertension Reviews PERIPHERAL VASCULAR DISEASE-
CiteScore
4.80
自引率
0.00%
发文量
26
期刊介绍: Current Hypertension Reviews publishes frontier reviews/ mini-reviews, original research articles and guest edited thematic issues on all the latest advances on hypertension and its related areas e.g. nephrology, clinical care, and therapy. The journal’s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all clinicians and researchers in the field of hypertension.
期刊最新文献
Exploring the Challenges of Recruiting Older People for a Randomised Trial Assessing the Feasibility of Treating White Coat Hypertension in the UK General Practices: A Mixed-methods study. The New Editor-In-Chief Note. Treatment of Hypertension in Children. Screening for Hypertension in Adults of a Northern Delta Province in Vietnam. Highlights from the New European Society of Hypertension Guidelines Document.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1